MCM
RPRX icon

Manchester Capital Management’s Royalty Pharma RPRX Stock Holding History

Manchester Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.9K Buy
694
+107
+18% +$5.57K 0.01% 556
2026
Q1 		$28.2K Hold
587
– – ﹤0.01% 608
2025
Q4 		$22.7K Buy
587
+39
+7% +$1.49K ﹤0.01% 636
2025
Q3 		$19.3K Sell
548
-20
-4% -$724 ﹤0.01% 748
2025
Q2 		$20.5K Sell
568
-15
-3% -$497 ﹤0.01% 714
2025
Q1 		$18.1K Buy
583
+175
+43% +$5.55K ﹤0.01% 728
2024
Q4 		$10.4K Buy
+408
New +$10.8K ﹤0.01% 801
2022
Q1 		– Sell
-238
Closed -$9K – 1090
2021
Q4 		$9K Buy
+238
New +$9.25K ﹤0.01% 579
2021
Q1 		– Sell
-33
Closed -$2K – 764
2020
Q4 		$2K Buy
+33
New +$1.4K ﹤0.01% 620

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Manchester Capital Management's RPRX Position: Q2 2026 in Review

Manchester Capital Management increased its Royalty Pharma (RPRX) stake by 18% in Q2 2026, buying an estimated $5.57K and bringing the position to 694 shares worth $38.9K. The position accounts for 0.01% of the portfolio, ranked #556.

Manchester Capital Management first reported a position in RPRX in Q4 2020 and has held it in 9 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Manchester Capital Management held 694 shares of Royalty Pharma worth $38.9K as of Q2 2026.
  • Manchester Capital Management bought 107 Royalty Pharma shares in Q2 2026, an estimated $5.57K.
  • Royalty Pharma made up 0.01% of Manchester Capital Management's portfolio in Q2 2026, its #556 holding.
  • Manchester Capital Management first reported a position in Royalty Pharma in Q4 2020 and has held it in 9 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.